Lexaria Bioscience annual operating income
2014
2015
2016
2021
2022
2023
2024
2025
Lexaria Bioscience Operating Income Growth & History (LEXX)
Lexaria Bioscience's operating income was −$11.9M for fiscal 2025.
View full Lexaria Bioscience company overviewLexaria Bioscience annual operating income history
| Fiscal year | Period ended | Operating income | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-08-31 | −$11.9M | −$6.1M | — |
| 2024 | 2024-08-31 | −$5.8M | $780,892 | — |
| 2023 | 2023-08-31 | −$6.5M | $85,017 | — |
| 2022 | 2022-08-31 | −$6.6M | −$932,187 | — |
| 2021 | 2021-08-31 | −$5.7M | — | — |
| 2016 | 2016-08-31 | −$1.3M | $706,021 | — |
| 2015 | 2015-08-31 | −$2.0M | −$423,929 | — |
| 2014 | 2014-08-31 | −$1.6M | — | — |
Lexaria Bioscience quarterly operating income
Q3.13
Q3.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q1.18
Q2.18
Q3.21
Q3.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
Q3.26
| Fiscal quarter | Period ended | Operating income | Change | YoY change |
|---|---|---|---|---|
| Q3 2026 | 2026-05-31 | −$2.0M | $1.8M | — |
| Q2 2026 | 2026-02-28 | −$1.5M | $1.3M | — |
| Q1 2026 | 2025-11-30 | −$1.6M | $1.1M | — |
| Q4 2025 | 2025-08-31 | −$2.7M | −$485,533 | — |
| Q3 2025 | 2025-05-31 | −$3.8M | −$2.0M | — |
| Q2 2025 | 2025-02-28 | −$2.8M | −$2.1M | — |
| Q1 2025 | 2024-11-30 | −$2.7M | −$1.6M | — |
| Q4 2024 | 2024-08-31 | −$2.2M | −$1.1M | — |
| Q3 2024 | 2024-05-31 | −$1.7M | $657,946 | — |
| Q2 2024 | 2024-02-29 | −$668,005 | $655,620 | — |
| Q1 2024 | 2023-11-30 | −$1.1M | $556,277 | — |
| Q4 2023 | 2023-08-31 | −$1.1M | — | — |
| Q3 2023 | 2023-05-31 | −$2.4M | $17,473 | — |
| Q2 2023 | 2023-02-28 | −$1.3M | — | — |
| Q1 2023 | 2022-11-30 | −$1.7M | — | — |
| Q3 2022 | 2022-05-31 | −$2.4M | $148,214 | — |
| Q3 2021 | 2021-05-31 | −$2.6M | — | — |
| Q2 2018 | 2018-02-28 | −$1.4M | −$913,396 | — |
| Q1 2018 | 2017-11-30 | −$578,713 | −$178,160 | — |
| Q2 2017 | 2017-02-28 | −$464,982 | −$190,425 | — |
| Q1 2017 | 2016-11-30 | −$400,553 | $11,189 | — |
| Q4 2016 | 2016-08-31 | −$326,749 | $288,832 | — |
| Q3 2016 | 2016-05-31 | −$264,201 | $246,807 | — |
| Q2 2016 | 2016-02-29 | −$274,557 | $184,051 | — |
| Q1 2016 | 2015-11-30 | −$411,742 | −$13,669 | — |
| Q4 2015 | 2015-08-31 | −$615,581 | — | — |
| Q3 2015 | 2015-05-31 | −$511,008 | — | — |
| Q2 2015 | 2015-02-28 | −$458,608 | — | — |
| Q1 2015 | 2014-11-30 | −$398,073 | — | — |
| Q3 2014 | 2014-07-31 | −$567,954 | −$510,285 | — |
| Q3 2013 | 2013-07-31 | −$57,669 | — | — |
Lexaria Bioscience operating income trends
Between the periods ended 2014-08-31 and 2025-08-31, Lexaria Bioscience's operating income decreased from −$1.6M to −$11.9M, a change of −$10.3M. The latest reported quarter, Q3 2026, shows −$2.0M.
About the metric
What operating income means
Operating income is the profit or loss a company generates from its core business after cost of revenue and operating expenses, but before non-operating items such as interest and income taxes.
Calculation and source
SEC-reported operating income
TickerStat standardizes operating income reported in company SEC filings for aligned fiscal periods. It is not adjusted EBIT, an analyst estimate, or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Lexaria Bioscience source filings ↗